Who Owns Vaxcyte Company?

Who Owns Vaxcyte?

Understanding a company's ownership is key to grasping its direction and accountability. Vaxcyte, a clinical-stage biotech firm, transitioned to public ownership via its IPO on June 12, 2020, trading on the Nasdaq under 'PCVX'.

Founded in 2013, Vaxcyte focuses on innovative vaccines using its cell-free protein synthesis platform. Its market capitalization reached approximately $4.38 billion by July 31, 2025.

The company's journey began with founders Jeff Fairman and Grant Pickering. Post-IPO, ownership evolved, influencing its strategic path and governance.

Key stakeholders, including institutional investors and the board of directors, play significant roles in shaping the company's future, including the development of products like the Vaxcyte BCG Matrix.

Vaxcyte was established in 2013 by its co-founders, Jeff Fairman, PhD, and Grant Pickering, MBA. These individuals brought extensive experience in the biotechnology and vaccine development sectors, laying the groundwork for the company's future endeavors. Their combined expertise has been instrumental in shaping the company's direction and its approach to innovation in the field of immunotherapeutics.

Founding Visionaries

Grant Pickering, as Co-Founder and CEO, contributes over 30 years of experience in vaccine and immunotherapeutic drug development and commercialization. His background includes leadership roles at Mymetics Corporation and Juvaris BioTherapeutics, alongside experience as an executive-in-residence at Kleiner, Perkins, Caufield & Byers.

Biotech Expertise

Jeff Fairman, PhD, serves as Co-Founder and VP, bringing more than 25 years of experience in the biotech industry. He has led research at various platform companies and co-founded Juvaris BioTherapeutics, where his work advanced immunotherapeutic and vaccine adjuvant platforms.

Early Capital Infusion

Before its initial public offering, Vaxcyte secured a total of $347 million through 8 funding rounds. This early capital was crucial for advancing the company's proprietary cell-free protein synthesis platform and its lead vaccine candidates.

Key Early Investors

Prominent early institutional investors in Vaxcyte included Frazier Healthcare Partners, TPG, and Abingworth. These firms provided essential financial backing and strategic guidance during the company's formative stages.

Latest Pre-IPO Funding

The company's Series D funding round, which closed on April 3, 2020, raised $110 million. Participants in this round included RA Capital Management and Janus Henderson Investors, underscoring continued investor confidence.

Foundation of Growth

The initial ownership structure at Vaxcyte's inception is not publicly detailed. However, the significant venture capital funding from early backers was foundational for the company's research and development efforts, enabling the progression of its innovative technologies.

The early ownership of Vaxcyte was shaped by its founders, Jeff Fairman, PhD, and Grant Pickering, MBA, who established the company in 2013. While the precise initial equity distribution remains private, the company's trajectory was significantly influenced by its ability to attract substantial venture capital. This early financial support, totaling $347 million across multiple rounds prior to its IPO, was critical for developing its core technologies and advancing its pipeline. Key investors such as Frazier Healthcare Partners, TPG, and Abingworth played a vital role in this early stage, with RA Capital Management and Janus Henderson Investors participating in the latest pre-IPO funding round in April 2020. Understanding these early stakeholders is key to grasping the Vaxcyte company history ownership and its subsequent growth.

Founders and Early Backers

Vaxcyte's foundation in 2013 was driven by the expertise of co-founders Jeff Fairman, PhD, and Grant Pickering, MBA. Their combined experience in biotechnology and vaccine development provided the initial vision and leadership. The company's early growth was significantly bolstered by substantial venture capital funding, which enabled the advancement of its proprietary platforms and vaccine candidates.

• Co-Founders: Jeff Fairman, PhD, and Grant Pickering, MBA
• Grant Pickering's Role: Co-Founder and CEO with extensive industry experience
• Jeff Fairman's Role: Co-Founder and VP with a strong research background
• Total Pre-IPO Funding: $347 million over 8 rounds
• Notable Early Investors: Frazier Healthcare Partners, TPG, Abingworth
• Latest Pre-IPO Round (Series D): $110 million on April 3, 2020
• Key Participants in Series D: RA Capital Management, Janus Henderson Investors
• Impact of Funding: Enabled development of cell-free protein synthesis platform and lead vaccine candidates

Complete Vaxcyte Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Vaxcyte, Inc. became a publicly traded entity on June 12, 2020, through an initial public offering that generated substantial capital. Subsequent equity offerings in 2024 further bolstered its financial standing, significantly influencing its ownership structure.

Institutional investors are the dominant force in Vaxcyte's ownership landscape. As of May 2025, a significant number of institutional entities have reported their holdings, collectively owning a substantial portion of the company's shares. This widespread institutional interest underscores the confidence in Vaxcyte's development pipeline and future prospects. Understanding who owns Vaxcyte is key to grasping its corporate governance and strategic direction.

Vaxcyte's Major Stakeholders

Institutional investors hold the majority of Vaxcyte's shares, indicating significant professional investment in the company.

• Fmr LLC: 12,512,234 shares (as of March 31, 2025)
• RA Capital Management, L.P.: 12,189,149 shares (as of March 31, 2025)
• Vanguard Group Inc.: 12,043,805 shares (as of March 31, 2025)
• Janus Henderson Group Plc: 11,765,481 shares (as of March 31, 2025)
• Blackrock, Inc.: 10,579,477 shares (as of March 31, 2025)
• Other notable holders include Wellington Management Group LLP, Capital Research Global Investors, and State Street Corp.
• Individual shareholders represent a small fraction of ownership at 0.95%.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Vaxcyte's Board of Directors is instrumental in guiding the company's strategic direction and corporate governance. The board comprises a mix of executive and independent directors, bringing diverse expertise and representation from key stakeholders. As of May 2025, Dr. Olivier Brandicourt, formerly CEO of Sanofi S.A., joined the board as an independent Class III director.

Vaxcyte operates with a straightforward one-share-one-vote structure for its common stock, meaning each share of Stock A carries a single vote. The company's 2020 Equity Incentive Plan allows for stock-based awards, which generally include voting rights for recipients, though the board can stipulate otherwise. There are no publicly disclosed dual-class share structures or special voting rights that concentrate control. However, significant corporate actions, such as amendments to the company's certificate of incorporation, require a supermajority vote of at least 66 2/3% of the total voting power. The company has not experienced any recent public proxy battles or activist investor campaigns, suggesting a stable shareholder base and governance structure.

Understanding Vaxcyte's Shareholder Power

Vaxcyte's voting power is distributed through its common stock, with each share typically holding one vote. This structure ensures that Vaxcyte ownership is directly tied to voting influence.

• One-share-one-vote structure for common stock.
• Stock A grants 1 vote per quantity.
• 2020 Equity Incentive Plan includes stock awards with voting rights.
• No publicly reported dual-class shares or golden shares.
• Significant corporate changes require a 66 2/3% supermajority vote.

Vaxcyte Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Recent financial maneuvers and clinical advancements have reshaped Vaxcyte's ownership landscape. The company's successful completion of two follow-on equity offerings in 2024, yielding approximately $2.2 billion, has significantly bolstered its financial standing. This strategic capital infusion supports ongoing development, including a dedicated commercial manufacturing facility.

Institutional investors continue to be the primary holders of Vaxcyte stock, with 831 institutions collectively owning over 180 million shares as of May 2025. While some institutions like Jennison Associates LLC and Northern Trust Corp. adjusted their holdings in Q1 2025, others such as UBS Group AG and Novo Holdings notably increased their investments. This dynamic activity reflects active portfolio management by major funds, underscoring the ongoing interest in Vaxcyte's potential. The company's stock price saw a notable decrease of 55.88% from July 31, 2024, to July 30, 2025, closing at $34.81 per share on the latter date.

Institutional Investor Activity

As of May 2025, 831 institutions held over 180 million shares. UBS Group AG and Novo Holdings significantly increased their stakes in Q1 2025.

Financial Health and Investment

Vaxcyte reported $3.0 billion in cash as of March 31, 2025. R&D expenses rose to $148.1 million in Q1 2025, supporting key vaccine programs.

Clinical Development Pipeline

The company is advancing its pneumococcal conjugate vaccine programs, with a Phase 3 study for the adult program anticipated by mid-2025. A new candidate, VAX-XL, was announced in March 2025.

Stock Performance and Ownership Trends

Vaxcyte's stock experienced a 55.88% decline between July 2024 and July 2025. Ownership trends are influenced by active institutional trading and strategic R&D investments, which are key to understanding Revenue Streams & Business Model of Vaxcyte.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE